Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Biological therapies, such as a dendritic cell vaccine made with a patient's cancer cells, may stimulate the immune system in different ways and stop cancer cells from growing. PURPOSE: This phase I/II trial is studying the side effects of dendritic cell vaccine and to see how well it works in treating patients with indolent B-cell lymphoma or multiple myeloma.

Detailed Description
-----------------
OBJECTIVES: Evaluation of feasibility of dendritic cell (DC)-based vaccination program using autologous tumor cells and/or lysates in patients with indolent B cell lymphomas or multiple myeloma as an adjuvant therapy to induce immune response in remission after cytoreductive treatment. Evaluation of the immune response of patients treated with this regimen. Evaluation the progression-free survival of patients treated this regimen. Evaluate the adverse events of this regimen in these patients. OUTLINE: Patients receive intranodal (under ultrasound guidance) or subcutaneous vaccinations of adjuvant electrofusion hybrids of autologous dendritic cells (DC) with autologous lymphoma cells, electrofusion hybrids of allogeneic DC with autologous lymphoma cells, and/or autologous DC pulsed with autologous tumor lysate cells in weeks 0, 2, 4, 8, 12, 18, 26, and 50.

Official Title
-----------------
Vaccination of Lymphoma Patients With Dendritic Cell-lymphoma Cell Hybrids and Dendritic Cells Pulsed With Tumor Lysates

Conditions
-----------------
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm

Intervention / Treatment
-----------------
* Biological: autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine
* Biological: autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine
* Biological: autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Histologically confirmed diagnosis of 1 of the following: Mantle cell lymphoma Marginal zone lymphoma Follicular lymphoma Small lymphocytic lymphoma/chronic lymphocytic leukemia Multiple myeloma Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia Diffuse large B-cell lymphoma Adequate sample size and lymphoma cell content in the fresh tissue collected No bulky or progressive disease PATIENT CHARACTERISTICS: Life expectancy > 3 months No evidence of lung, heart, liver, or renal failure or severe neurologic disorder No autoimmune disease or atopic allergy No HIV positivity No other malignancy PRIOR CONCURRENT THERAPY: Not specified

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 120 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine|nan|
|Biological: autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine|nan|
|Biological: autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immune response |  |  | 
| Progression-free survival |  |  | 
| Adverse events |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dendritic cell vaccine, tumor cell lysate, lymphoma